logo image
search icon
Global Fabry Disease Treatment Market

Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Trial Phase, By Treatment Type (Enzyme Replacement Therapy (ERT), Chaperone Therapy), By Region, And by Segment Forecasts, 2023-2031

Report ID : 1451 | Published : 2023-04-18 | Pages: 180 | Format: PDF/EXCEL

The Fabry Disease Treatment Market Size is valued at 1526.26 Million in 2022 and is predicted to reach 3052.15 Million by the year 2031 at an 8.21 % CAGR during the forecast period for 2023-2031.

Fabry Disease Treatment Market

Fabry disease has been linked to several systemic signs and consequences, including metabolic abnormalities. In Fabry disease, sphingolipid metabolism is reduced, resulting in multiple organ failures and death. Government agencies have also launched programs in response to the disease's increasing consequences and the necessity for precise diagnosis and treatment. The creation of a potential biomarker for tracking and predicting disease severity and potential progression, as well as any treatment intervention's success, all help drive the fabry disease market forward. The increased financial burden of people with uncommon genetic disorders such as Fabry and the expensive treatment costs may limit the growth of the Fabry disease treatment market.

Adopting advanced technology in research procedures is one of the primary factors of the fabry disease market growth. Complications in physiological systems, such as the cardiac and urinary systems, are projected to increase the demand for reliable therapy due to the hereditary nature and severity of the disease. Extensive R&D activities are one of the market's most valuable drivers. Incorporating innovative oral medication options can help overcome the relative lack of efficacy of enzyme replacement therapy, which is partly caused by antibody development. Furthermore, due to fabry disease patients' poor quality of life, there is significant patient readiness to pay for expensive therapies in the fabry disease market.

 

Market Segmentation:

The fabry disease treatment market is segmented on the treatment. Based on treatment, the market is segmented into Enzyme Replacement Therapy (ERT) ((By Drug Type (Agalsidase Alpha, Agalsidase Beta), (By End-use (Physician office, Home settings)), and Chaperone Therapy.

The Enzyme Replacement Treatment Segment Witnessed Growth At A Rapid Rate.

Enzyme replacement treatment grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. ERT is intended to aid in identifying underlying disease causes and the breakdown of fatty molecules. Replagal enzyme replacement treatment, for example, was developed to replace human alpha-galactosidase A, a prevalent defect in fabry disease patients. Substantial application scope and the development of novel therapies will thus drive segmental growth over the forecasted term. The segment's dominance is supported by strong sales of fabrazyme and replagal, as well as the prospective approval of promising pipeline products. However, introducing new effective therapeutic options, such as gene therapies, is critical for a significant rise in patient benefits.

The North American Fabry Disease Treatment Market Holds A Significant Regional Revenue Share.

The North American Fabry disease treatment market is expected to register the highest market share in revenue soon. Higher acceptance of innovative therapeutics, improved healthcare facilities, and advantageous reimbursement policies contribute to the region's market growth. Coverage of pricey treatments such as fabrazyme by health insurance programs and beneficial governmental healthcare regulations also encourage pharmaceutical companies to enhance R&D spending on rare diseases. In addition, Asia Pacific is projected to grow rapidly in the global fabry disease treatment market. Government agencies have also launched programs in response to the disease's increasing consequences and the necessity for precise diagnosis and treatment. Because of rising healthcare spending and improved infrastructure, Asia Pacific presents enormous growth prospects for pharmaceutical companies.

Competitive Landscape

Some major key players in the Fabry Disease Treatment Market:

  • Sanofi SA,
  • Takeda Pharmaceuticals Co,
  • Amicus Therapeutics, Inc,
  • JCR Pharmaceuticals Co Ltd,
  • ISU Abxis Co. Ltd.,
  • Avrobio Inc.,
  • Greenovation Biotech GmbH,
  • Idorsia Pharmaceuticals Ltd.,
  • Moderna Therapeutics Inc.,
  • Protalix Biotherapeutics Inc.,
  • Shire Plc

  

Fabry Disease Treatment Market Report Scope

 

Report Attribute

Specifications

Market Size Value In 2022

USD 1526.26 Million

Revenue Forecast In 2031

USD 3052.15  Million

Growth Rate CAGR

CAGR of 8.21 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

Treatment Type

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Sanofi SA, Takeda Pharmaceuticals Co, Amicus Therapeutics, Inc, JCR Pharmaceuticals Co Ltd, ISU Abxis Co. Ltd., Avrobio Inc., Greenovation Biotech GmbH, Idorsia Pharmaceuticals Ltd., Moderna Therapeutics Inc., Protalix Biotherapeutics Inc., and Shire Plc

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements. Find purchase alternatives.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Fabry Disease Treatment Market Snapshot

Chapter 4. Global Fabry Disease Treatment Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Treatment Type Estimates & Trend Analysis

5.1. by Treatment Type & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2023 to 2031 for the following by Treatment Type:

5.2.1. Enzyme Replacement Therapy

5.2.2. Oral Chaperone Therapy

5.2.3. Other Treatments

Chapter 6. Market Segmentation 2: by Route of Administration Estimates & Trend Analysis

6.1. by Route of Administration & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2023 to 2031 for the following by Route of Administration:

6.2.1. Oral Route

6.2.2. Intravenous Route

Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis

7.1. by Distribution Channel & Market Share, 2019 & 2031

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2023 to 2031 or the following by Distribution Channel:

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

Chapter 8. Fabry Disease Treatment Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Fabry Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2023-2031

8.1.2. North America Fabry Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2023-2031

8.1.3. North America Fabry Disease Treatment Market revenue (US$ Million) by Distribution Channel, 2023-2031

8.1.4. North America Fabry Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.2. Europe

8.2.1. Europe Fabry Disease Treatment Market revenue (US$ Million) by Treatment Type, 2023-2031

8.2.2. Europe Fabry Disease Treatment Market revenue (US$ Million) by Route of Administration, 2023-2031

8.2.3. Europe Fabry Disease Treatment Market revenue (US$ Million) by Distribution Channel, 2023-2031

8.2.4. Europe Fabry Disease Treatment Market revenue (US$ Million) by country, 2023-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Fabry Disease Treatment Market revenue (US$ Million) by Treatment Type, 2023-2031

8.3.2. Asia Pacific Fabry Disease Treatment Market revenue (US$ Million) by Route of Administration, 2023-2031

8.3.3. Asia-Pacific Fabry Disease Treatment Market revenue (US$ Million) by Distribution Channel, 2023-2031

8.3.4. Asia Pacific Fabry Disease Treatment Market revenue (US$ Million) by country, 2023-2031

8.4. Latin America

8.4.1. Latin America Fabry Disease Treatment Market revenue (US$ Million) by Treatment Type, 2023-2031

8.4.2. Latin America Fabry Disease Treatment Market revenue (US$ Million) by Route of Administration, 2023-2031

8.4.3. Latin America Fabry Disease Treatment Market revenue (US$ Million) by Distribution Channel, 2023-2031

8.4.4. Latin America Fabry Disease Treatment Market revenue (US$ Million) by country, 2023-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Fabry Disease Treatment Market revenue (US$ Million) by Treatment Type, 2023-2031

8.5.2. Middle East & Africa Fabry Disease Treatment Market revenue (US$ Million) by Route of Administration, 2023-2031

8.5.3. Middle East & Africa Fabry Disease Treatment Market revenue (US$ Million) by Distribution Channel, 2023-2031

8.5.4. Middle East & Africa Fabry Disease Treatment Market revenue (US$ Million) by country, 2023-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Sanofi SA

9.2.2. Takeda Pharmaceuticals Co.

9.2.3. Amicus Therapeutics, Inc.

9.2.4. JCR Pharmaceuticals Co Ltd.

9.2.5. ISU Abxis Co. Ltd

9.2.6. Other Prominent Players

 

 

Segmentation Of Fabry Disease Treatment Market

 

By Treatment

• Enzyme Replacement Therapy (ERT)
• Chaperone Therapy

Fabry Disease Treatment Market

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Fabry Disease Treatment Market?

The Fabry Disease Treatment Market is expected to grow at an 8.21 % CAGR during the forecast period for 2023-2031.

Sanofi SA, Takeda Pharmaceuticals Co, Amicus Therapeutics, Inc, JCR Pharmaceuticals Co Ltd, ISU Abxis Co. Ltd., Avrobio Inc., Greenovation Biotech Gmb

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach